MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls

MAIA Biotechnology, Inc. (MAIA) has disclosed a new risk, in the Share Price & Shareholder Rights category.

MAIA Biotechnology, Inc. faces a significant business risk due to potential delisting from NYSE American for non-compliance with stockholders’ equity requirements. With stockholders’ equity at a mere $0.48 million and consecutive years of losses, they fall short of the $2 million and $4 million thresholds for continued listing. If delisted, MAIA could suffer reduced liquidity and trading price for its common stock, alongside other adverse effects including diminished research coverage and investor confidence. The transition to over-the-counter markets could also impose more stringent regulations and hinder future capital-raising efforts.

The average MAIA stock price target is $14.00, implying 563.51% upside potential.

To learn more about MAIA Biotechnology, Inc.’s risk factors, click here.